SHERLOCK, a rapid CRISPR-based diagnostic, detects Candida auris and antifungal resistance mutations in patient samples in under an hour.

Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the, "Next-Generation ...

Panther is inviting pharmaceutical and biotechnology partners to co-develop higher-efficacy, lower-toxicity, shelf-stable therapies using its MAP platform. We believe rethinking how treatments are ...

Arrayjet, an inventor and leading provider of high-speed inkjet microarray technology, has announced the opening of its first ...

Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive Officer to lead the commercialisation of the Company’s proprietary high‑density ...

Brisbane-based Vaxxas has appointed David Peacock to lead the push to bring its vaccine patch technology to market.

Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

A recent study on DNA microarray technology highlights its essential role in enabling high-throughput analysis of large numbers of genes through arrays of probes integrated on a solid-phase support.

Pimple patches seem to be soaring in popularity—and a newly invented type that makes zits disappear without pain or irrtitation in mere days could soon be all the rage. Researchers have created a ...